CPD-017 by Kataoka Corporation to Streamline iPSC Processing for the US Market

CPD-017 by Kataoka Corporation to Streamline iPSC Processing for the US Market

Los Angeles, California, May 25th, 2022 – Kataoka Corporation (Kyoto, Japan) and Kataoka-SS America Corporation (Carson, CA) have developed the CPD-017, a cell processing platform that uses cutting edge laser and AI technology to purify adherent iPSC cultures.

The CPD-017 uses a platform of integrated technologies to process iPSC samples; built-in phase contrast and fluorescence microscopes to image samples, a tailored, machine-learning AI model to process the images and identify spontaneously differentiated cells, and laser treatment to target discrepant cells with minimal stress to the surrounding environment.

The CPD-017 is now available for purchase – Kataoka Corporation is pleased to announce its first US-based customer, the Cedars-Sinai Medical Center Biomanufacturing Center, a division of the Board of Governors Regenerative Medicine Institute.

More information about Kataoka Corporation and the CPD-017 can be found at Requests for further product and sales-related information can be submitted to, or through the inquiries form on the website.


About Kataoka Corporation

Kataoka Corporation, headquartered in Kyoto, Japan, with U.S. offices in Carson, CA and Reno, NV, is a leader in precision laser technology, and has applications in various niches including charge-discharge battery inspection systems, and Life Sciences in addition to laser drilling and welding machines.

Leave a Reply

Your email address will not be published. Required fields are marked *